Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2025 (Issued December 15, 2025; Filed December 16, 2025)
Context: This filing announces the first global marketing authorisation of Exdensur (depemokimab) by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The approval covers two indications: severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for any financial metrics. This document is a regulatory announcement regarding a specific product approval and does not contain financial statements or performance data.
Material Changes and Product Milestones
- Regulatory Approval: Exdensur received UK approval as the first ultra-long-acting biologic with twice-yearly dosing for respiratory diseases.
- Clinical Efficacy (Asthma): Pooled SWIFT trial results showed a 54% reduction in clinically significant exacerbations (rate ratio 0.46) and a 72% reduction in exacerbations requiring hospitalisation or emergency department visits compared to placebo.
- Clinical Efficacy (CRSwNP): Pooled ANCHOR trial results demonstrated significant improvement in nasal polyp scores and nasal obstruction compared to placebo.
- Safety Profile: Depemokimab was well-tolerated with side effect rates and severity similar to placebo across trials.
Guidance, Outlook, and Risks
Outlook and Regulatory Pipeline
- Global Expansion: Regulatory decisions are expected in the US, Japan, EU, and China starting December 2025 and continuing through the first half of 2026.
- EU Status: Depemokimab recently received a positive Committee for Medicinal Products for Human Use (CHMP) opinion in the EU.
- Pipeline: Ongoing Phase III trials include OCEAN (eosinophilic granulomatosis with polyangiitis), DESTINY (hyper eosinophilic syndrome), and ENDURA/VIGILANT (COPD with type 2 inflammation).
Risks and Contingencies
The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 results, including regulatory uncertainties and clinical trial outcomes.
Investor Verification Checklist
- Verify the timeline for upcoming regulatory decisions in the US, Japan, EU, and China (expected Dec 2025 – H1 2026).
- Confirm the commercial launch strategy and pricing for Exdensur in the UK following MHRA approval.
- Review the "Risk Factors" section of the 2024 Form 20-F for details on regulatory and clinical uncertainties.
- Monitor the publication of the Summary of Product Characteristics and Patient Information leaflets on the MHRA website (expected within 7 days of approval).
- Assess the competitive landscape for ultra-long-acting biologics in the respiratory sector.